Globally, 300,000 people are currently living with Duchenne Muscular Dystrophy. Did you know that one in 5,000 newborn boys in the world is affected by Duchenne Muscular Dystrophy?
Living with Duchenne Muscular Dystrophy is a journey marked by both physical challenges and emotional resilience. Historically, individuals with DMD lived only into their late teens or early 20s. Today, modern standards of care extend average survival well into the late 20s and early 30s, with select patients reaching their 40s.
Duchenne Muscular Dystrophy (DMD) is a rare progressive disorder.The first symptoms of DMD are normally identified in early childhood by parents. People with DMD are missing muscle-protecting protein. This is due to a fault in the gene producing dystrophin.
Importantly, those living with DMD have issues with muscles becoming weaker over time until they affect the whole body. It is caused by a mutation on the X-chromosome; that is why mainly males are affected. First walking becomes difficult, then other motor functions follow and ultimately they affect the ability to breathe, as well as the function of the heart as the heart is a muscle too.
The missing protein also has a function in the brain, so learning and behaviour issues can also be part of the disease. Duchenne muscular dystrophy is one of the most common pediatric genetic rare diseases, the United Nations General Assembly decided to designate September 7, as World Duchenne Awareness Day since 2024.
The theme ‘Access Changes Lives’ is both a call to action and a shared commitment. It challenges policymakers, healthcare professionals, researchers, industry leaders, patient organisations, educators, and communities to work together to identify and remove barriers wherever they exist. It recognizes that true progress is measured not only by scientific breakthroughs, but by ensuring that every person living with Duchenne has the opportunity to access the care, support, and opportunities they need to live a full and meaningful life.
Access to healthcare is always problematic especially for marginalised communities. Access is a fundamental driver of better outcomes for people living with Duchenne. It means ensuring equitable access to accurate information, early and timely diagnosis, multidisciplinary standards of care, specialist services, clinical trials, and innovative therapies.
As scientific understanding advances and new treatment options continue to emerge, it is essential that these developments translate into meaningful benefits for every individual and family affected by Duchenne, regardless of where they live, their socioeconomic circumstances, or the limitations of their healthcare system.
Access also means empowering people and families with the knowledge, resources, and support they need to make informed decisions throughout their Duchenne journey. From diagnosis through adulthood, access to reliable information, coordinated care, assistive technologies and community support can have a profound impact on health outcomes, wellbeing, and quality of life.
Beyond healthcare, access is about inclusion and participation. People living with Duchenne should have the opportunity to engage fully in all aspects of society, including education, employment, sports and recreation, cultural activities, travel, and social life. Achieving this requires accessible environments, improved mobility and transportation, the removal of physical and social barriers, and a collective commitment to ensuring equal opportunities for all.
Even though remarkable progress has been made in research, care, and treatment over recent decades, significant disparities in access continue to exist across countries and communities around the world. Too many individuals and families still face barriers that limit their opportunities, health outcomes, and participation in society.
Duchenne Muscular Dystrophy is named after Dr Duchenne de Boulogne, who was one of the first to report the disease in detail in the 1860s.
WORLD DUCHENNE AWARENESS DAY
The United Nations General Assembly encouraged stakeholders to actively raise awareness on the specific challenges and needs faced by individuals and families in the rare diseases community through national campaigns, educational programmes and information dissemination, with the goal of fostering greater understanding and empathy towards those affected by rare diseases and promoting global solidarity.
World Duchenne Awareness Day 2026 must be more than another day of awareness.
It must be a call for access, fairness and action.
– Wayne Campbell is an educator and social commentator with an interest in development policies as they affect culture and or gender issues. Email feedback to waykam@yahoo.com and columns@gleanerjm.com. ONLINE ONLY COMMENTARY.
